Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pituitary Neoplasms 3Nelson Syndrome 2Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Meningioma 1Carcinoma, Intraductal, Noninfiltrating 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × pasireotide × Clear all
NCT00813592 2014-06-11

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

University of Utah

Phase 2 Terminated
2 enrolled 6 charts
CNS

Meningioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡